Traduction de «made » (Néerlandais → Français) :

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

ESW: één-seconde waarde FVC: geforceerde vitale capaciteit MMMF: Man-Made Mineral Fibres MMVF: Man-Made Vitreous Fibres TEM: transmissie-elektronenmicroscopie TWA: Time Weighted Average (tijd-gewogen-gemiddelde blootstelling) TLV: Threshold Limit Values
AES: alkaline earth silicates CVF : capacité vitale forcée FCR : fibres céramiques réfractaires FVS : Fibres Vitreuses Synthétiques MMVF : Man-Made Vitreous Fibres TWA : Time Weighted Average (exposition moyenne pondérée par le temps) TLV : Threshold Limit Values VEMS : volume expiré en une seconde

Deze kunstmatige vezels vallen onder de Angelsaksische benaming MMVF (Man-Made Vitreous Fibres, dat de vroegere term MMMF voor " Man-Made Mineral Fibres" vervangt).
On rassemble ces fibres artificielles sous le terme anglo-saxon de MMVF (Man-Made Vitreous Fibres) et anciennement sous le vocable MMMF (Man-Made Mineral Fibres).

The recommendations made in this report are based on the available epidemiological data, the main observations that have been made with regard to the problem and an inventory of the actions already put in place in Belgium.
Les recommandations émises découlent des données épidémiologiques disponibles, des principaux constats établis par rapport au problème et d’un inventaire d’actions déjà mises en place en Belgique.

In 2008 a number of presentations were also made to faculties of veterinary science and regional veterinary associations. Similar presentations will also be organised in 2009.
In 2008 a number of presentations were also made to faculties of veterinary science and regional veterinary associations. Similar presentations will also be organised in 2009.

At the start of 2008 forms and user guides were sent to managers of cell and tissue banks in order to encourage voluntary reporting in expectation of the national transposition of the relevant European directive which made
At the start of 2008 forms and user guides were sent to managers of cell and tissue banks in order to encourage voluntary reporting in expectation of the national transposition of the relevant European directive which made

The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.
The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.

In the course of 2008 there were at least another 99 early phase trials of which 43 trials being carried out for the first time in humans, 164 phase I trials (including those not falling under the definition of an early phase trial), 176 phase II trials and 223 phase III trials. The database currently does not always allow a distinction to be made between early phase trials as defined above and later phases.
In the course of 2008 there were at least another 99 early phase trials of which 43 trials being carried out for the first time in humans, 164 phase I trials (including those not falling under the definition of an early phase trial), 176 phase II trials and 223 phase III trials. The database currently does not always allow a distinction to be made between early phase trials as defined above and later phases.

Efforts will be made to ensure efficient harmonisation of the standpoint adopted by the different FAMHP representatives and the circulation of those standpoints within the FAMHP.
Efforts will be made to ensure efficient harmonisation of the standpoint adopted by the different FAMHP representatives and the circulation of those standpoints within the FAMHP.

Provision has been made for the organised exchange of information with the national scientific commissions which give final opinions (e.g. evaluation commissions for medicines) and with the representatives on the international scientific or regulatory committees (e.g. CHMP, CVMP, CMD(h), CMD(v), COMP, PDCO).
Provision has been made for the organised exchange of information with the national scientific commissions which give final opinions (e.g. evaluation commissions for medicines) and with the representatives on the international scientific or regulatory committees (e.g. CHMP, CVMP, CMD(h), CMD(v), COMP, PDCO).